About ICASA / ICASA - International Collaboration on ADHD and Substance Abuse

Contact details ICASA participants

15 countries, 50 participants

Australia

Jesse Young PhD(c), MPH, BSc

Centre for Mental Health, The University of Melbourne
https://mspgh.unimelb.edu.au/centres-institutes/centre-for-mental-health
jesse.young@unimelb.edu.au

Dr. Dianne Grocott

Private Practice Psychiatry
Melbourne
grocott5@bigpond.com

Sharlene Kaye PhD

Justice Health & Forensic Mental Health Network, Matraville, NSW, 2036
www.justicehealth.nsw.gov.au
s.kaye@unsw.edu.au; Sharlene.goodhew@justicehealth.nsw.gov.au

Belgium

Prof. dr. Geert Dom

Antwerp University & Hospital, Addiction Psychiatry
Psychiatric Center Alexian Brothers
geert.dom@uantwerpen.be

Sofie Verspreet

Multiversum, Mental Health care.
sofie.verspreet@fracarita.org

Dr. Cleo L. Crunelle, PhD PhD

Department of Psychiatry | University Hospital Brussels (UZ Jette)
Toxicological Center | University of Antwerp
http://www.uzbrussel.be/u/view/nl/127510-Psychiatrie.html
cleo.crunelle@gmail.com

Prof. Dr. Frieda Matthys

Department of Psychiatry | University Hospital Brussels (UZ Jette)
http://www.uzbrussel.be/u/view/nl/127510-Psychiatrie.html
frieda.matthys@gmail.com

Drs. Michiel van Kernebeek

University Hospital Brussels (UZ Jette)
http://www.uzbrussel.be/
michielvankernebeek@gmail.com

Denmark

Prof. Søren Dalsgaard

The National Centre for Register-based Research, School of Business and Social Sciences, Department of Economics and Business Economics, Aarhus University.
www.ncrr.au.dk
sdalsgaard@econ.au.dk

France

Florence Vorspan MD, PhD

MCU-PH
Responsable d'Unité Fonctionnelle
Addictologie Ambulatoire
Département de Psychiatrie et de Médecine Addictologique
Hôpital Fernand Widal
florence.vorspan@aphp.fr

Maeva Fortias MD

CSAPA Espace Murger
Hôpital Fernand Widal
maeva.fortias@aphp.fr

Romain Icick MD, PhD

CSAPA Espace Murger
Hôpital Fernand Widal
romain.icick@aphp.fr

Emily Karsinti MSc

CSAPA Espace Murger
Hôpital Fernand Widal
emily.karsinti@aphp.fr

Germany

Dr. med. Mathias Luderer

Dpt. of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt
http://www.psychiatrie.uni-frankfurt.de/60397413/english
Mathias.Luderer@kgu.de

Prof. Dr. Falk Kiefer

Chair in Addiction Research, University of Heidelberg,
Head, Department of Addictive Behavior and Addiction Medicine
Central Institute of Mental Health (CIMH)
Falk.Kiefer@zi-mannheim.de

Prof. (apl.) Dr. Sabine Vollstädt-Klein

Head of research group on Neuroimaging of Addictive Behaviour
Central Institute of Mental Health (CIMH), Medical Faculty Mannheim / Heidelberg University
Department of Addictive Behaviour and Addiction Medicine
s.vollstaedt-klein@zi-mannheim.de

Anne Juppe

Central Institute of Mental Health (CIMH), Medical Faculty Mannheim / Heidelberg University
Department of Addictive Behaviour and Addiction Medicine
Anne.Juppe@zi-mannheim.de

Hungary

Máté Kapitány-Fövény PhD

Semmelweis University - Faculty of Health Sciences, Department of Addictology, Budapest
http://etk.semmelweis.hu/etk.html
Nyírő National Institute of Psychiatry and Addictions, Drug Outpatient Centre, Budapest
http://nygy-opai.hu/
m.gabrilovics@gmail.com

Prof. Zsolt Demetrovics

Institute of Psychology, ELTE Eötvös Loránd University, Budapest
https://www.ppk.elte.hu/en
demetrovics@t-online.hu

Csaba Barta, MD, PhD

Institute of Medical Chemistry, Molecular Biology and Pathobiochemistry
barta.csaba@med.semmelweis-univ.hu

Israel

Sharon Rabinovitz PhD

The Unit for Excellence in Research & Study of Addiction (ERSA), School of Criminology, University of Haifa
sharonrs@univ.haifa.ac.il; sharonrs123@gmail.com

Ortal Slobodin, Ph.D

Senior lecturer
Department of Education, Ben-Gurion University, Beer-Sheva
http://in.bgu.ac.il/Pages/default.aspx
Ortal.slobodin@gmail.com

Norway

Arvid Skutle Assoc Prof.

Research director
The Bergen Clinics Foundation
skua@bergenclinics.no

Puerto Rico

Maria C. Velez-Pastrana, Ph.D.

Universidad Carlos Albizu, Ph.D. Program in Clinical Psychology, San Juan
http://www.albizu.edu/
mvelez@sju.albizu.edu

Rafael A. Gonzalez, PhD

East London NHS Foundation Trust
Child and Adolescent Mental Health Service (CAMHS) - ADHD clinic, London
https://www.elft.nhs.uk/service/48/Child-and-Family-Consultation-Service
rafael.gonzalez1@nhs.net or rafael.gonzalez24@upr.edu

Spain

Prof. J. Antoni Ramos-Quiroga, MD, PhD

Head of Department of Psychiatry. Hospital Universitari Vall d’Hebron. CIBERSAM
Vall d’Hebron Institute of Research.
Professor of Psychiatry. Universitat Autònoma de Barcelona
https://www.vallhebron.com/ca
http://en.vhir.org/
jaramos@vhebron.net or ramosquiroga@gmail.com

Prof. Miguel Casas MD, PhD

Professor of Psychiatry. Universitat Autònoma de Barcelona
Department of Psychiatry. Hospital Universitari Vall d’Hebron. CIBERSAM
Vall d’Hebron Institute of Research
https://www.vallhebron.com/ca
http://en.vhir.org/
mcasas@vhebron.net

Dr. Lara Grau, MD, PhD

Coordinator of Addiction and Dual Pathology Section.
Department of Psychiatry. Hospital Universitari Vall d’Hebron. CIBERSAM
Associated Professor of Psychiatry. Universitat Autònoma de Barcelona
https://www.vallhebron.com/ca
http://en.vhir.org/
lgrau@vhebron.net

South Africa

Prof. Anneke Meyer

Limpopo University
jad1@mweb.co.za
Anneke.Meyer@ul.ac.za

Corne Coetzee

Limpopo University
coetzee.corne@ul.ac.za derek.corne@gmail.com

Prof. dr. Ilse Truter

Nelson Mandela Universiteit, Port Elizabeth

Judith Regnart

Nelson Mandela Universiteit, Port Elizabeth.

Sweden

Prof. Johan Franck, MD PhD

Clinical Director, Stockholm Centre for Dependency Disorders
Dept of Clinical Neuroscience, Karolinska Institutet
johan.franck@ki.se

Maija Konstenius, PhD

Section Head Outpatient Care, Stockholm Centre for Dependency Disorders
Dept of Clinical Neuroscience, Karolinska Institutet
maija.segle-konstenius@sll.se

Christoffer Brynte, MD

Resident (Psychiatry & Addiction)
Dept of Clinical Neuroscience, Karolinska Institutet
christoffer.brynte@ki.se

Anna Lena Hallström

Administrator
Stockholm Centre for Dependency Disorders
anna-lena.hallstrom@sll.se

Nasim Caspillo

Stockholm Center for Dependency Disorders
Research coordinator
nasim.caspillo@sll.se

Switzerland

Prof. Franz Moggi PhD, EMBA

University Hospital of Psychiatry and Psychotherapy
https://www.puk.unibe.ch/en/
franz.moggi@upd.unibe.ch

Yuliya Burren, MA

University Hospital of Psychiatry and Psychotherapy
https://www.puk.unibe.ch/en/
Yuliya.Burren@upd.ch

The Netherlands

Prof. dr. Wim van den Brink

Amsterdam Institute for Addiction Research
Academic Medical Center, University of Amsterdam
Department of Psychiatry
w.vandenbrink@amc.uva.nl

Arnt Schellekens Phd MD

Radboudumc, Donders centre for medical neuroscience, department of psychiatry
Nijmegen Institute for Scientist Practitioners in Addiction
www.radboudumc.nl/en/patient-care
www.NISPA.nl
arnt.schellekens@radboudumc.nl

Maria Paraskevopoulou

maria.paraskevopoulou@radboudumc.nl

Katelijne van Emmerik-van Oortmerssen, MD

Psychiatry residency at GGZ InGeest, Amsterdam, the Netherlands
katelijne.van.oortmerssen@arkin.nl

Alex Begeman

Psychologist
De Hoop ggz, Department Education and Research, Clinic VZ ZW
www.dehoop.org
A.Begeman@dehoop.org

Jacomine den Boer

De Hoop ggz
Coordinator Research
www.dehoop.org
j.denboer@dehoop.org

Prof. Robert Schoevers PhD, MD

University of Groningen, University Medical Center Groningen
www.psychiatrie.umcg.nl
r.a.schoevers@umcg.nl

Geurt van de Glind

United States of America

Frances R. Levin, MD

Kennedy-Leavy Professor of Psychiatry at CUMC, Director, Division on Substance Use Disorders, New York State Psychiatric Institute
Columbia University Medical Center, New York State Psychiatric Institute
frl2@cumc.columbia.edu

Stephen V. Faraone, Ph.D.

Distinguished Professor of Psychiatry and of
Neuroscience & Physiology, SUNY Upstate Medical University
Institute for Human Performance,
http://www.upstate.edu/psych/faculty.php?EmpID=MWTZIUAFGl
sfaraone@childpsychresearch.org

Brian Johnson MD

SUNY Upstate University
http://www.upstate.edu/psych/
johnsonb@upstate.edu

ICASA aims to contribute to a substantial decrease in the proportion of ADHD patients developing an addiction/substance use disorder (SUD) and to substantially improve the detection, diagnosis and treatment of patients having both ADHD and SUD.